Anticoagulation in Patients With Venous Thromboembolism and Cancer
NCT04618913
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- A VTE diagnosis
- Active cancer or history of cancer
- Treatment with VKA, NOAC (apixaban, rivaroxaban, dabigatran, edoxaban) or LMWH
- Age ≥ 18 years at the date of index VTE (Venous thromboembolic)
- Prior VTE diagnosis
- Diagnosis of prior atrial fibrillation
- Inferior Vena Cava (IVC) filter
- Prior exposure to (OAC) oral anticoagulation or (PAC)parenteral anticoagulation -
note: Prophylactic use of (OAC)/(PAC) allowed.
- Pregnancy
- More than one (OAC) oral anticoagulation or (PAC) parenteral anticoagulation dispensed
on the index date.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- London,
Descriptive Information | |||||||
---|---|---|---|---|---|---|---|
Brief Title | Anticoagulation in Patients With Venous Thromboembolism and Cancer | ||||||
Official Title | VICTORIE (VTE In Cancer - Treatment, Outcomes and Resource Use In Europe) | ||||||
Brief Summary | This study is a retrospective analysis of observational cohorts using data from prospectively collected administrative/claims data to investigate treatment patterns,healthcare resource utilisation (HCRU), direct and indirect costs (where feasible), and safety and effectiveness outcomes in patients with VTE and active cancer or patients with VTE and history of cancer who initiate anticoagulant treatment with a VKA, LMWH or NOACs. | ||||||
Detailed Description | Not Provided | ||||||
Study Type | Observational | ||||||
Study Design | Observational Model: Cohort Time Perspective: Retrospective | ||||||
Target Follow-Up Duration | Not Provided | ||||||
Biospecimen | Not Provided | ||||||
Sampling Method | Non-Probability Sample | ||||||
Study Population | Adult patients with a diagnosis of (VTE) venous thromboembolism and active cancer, or a history of cancer, being treated with anticoagulation. | ||||||
Condition |
| ||||||
Intervention |
| ||||||
Study Groups/Cohorts |
| ||||||
Publications * | Not Provided | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||||
Recruitment Information | |||||||
Recruitment Status | Not yet recruiting | ||||||
Estimated Enrollment | 1 | ||||||
Original Estimated Enrollment | Same as current | ||||||
Estimated Study Completion Date | September 30, 2021 | ||||||
Estimated Primary Completion Date | September 30, 2021 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
| ||||||
Sex/Gender |
| ||||||
Ages | 18 Years to 99 Years (Adult, Older Adult) | ||||||
Accepts Healthy Volunteers | No | ||||||
Contacts |
| ||||||
Listed Location Countries | United Kingdom | ||||||
Removed Location Countries | |||||||
Administrative Information | |||||||
NCT Number | NCT04618913 | ||||||
Other Study ID Numbers | B0661150 | ||||||
Has Data Monitoring Committee | No | ||||||
U.S. FDA-regulated Product |
| ||||||
IPD Sharing Statement |
| ||||||
Responsible Party | Pfizer | ||||||
Study Sponsor | Pfizer | ||||||
Collaborators | Not Provided | ||||||
Investigators |
| ||||||
PRS Account | Pfizer | ||||||
Verification Date | November 2020 |